Nature Communications (Oct 2020)
Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy
- Shumei Kato,
- Ki Hwan Kim,
- Hyo Jeong Lim,
- Amelie Boichard,
- Mina Nikanjam,
- Elizabeth Weihe,
- Dennis J. Kuo,
- Ramez N. Eskander,
- Aaron Goodman,
- Natalie Galanina,
- Paul T. Fanta,
- Richard B. Schwab,
- Rebecca Shatsky,
- Steven C. Plaxe,
- Andrew Sharabi,
- Edward Stites,
- Jacob J. Adashek,
- Ryosuke Okamura,
- Suzanna Lee,
- Scott M. Lippman,
- Jason K. Sicklick,
- Razelle Kurzrock
Affiliations
- Shumei Kato
- Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center
- Ki Hwan Kim
- Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center
- Hyo Jeong Lim
- Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center
- Amelie Boichard
- Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center
- Mina Nikanjam
- Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center
- Elizabeth Weihe
- Department of Radiology, UC San Diego Moores Cancer Center
- Dennis J. Kuo
- Division of Pediatric Hematology-Oncology, Rady Children’s Hospital-San Diego, University of California San Diego School of Medicine
- Ramez N. Eskander
- Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center
- Aaron Goodman
- Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center
- Natalie Galanina
- Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center
- Paul T. Fanta
- Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center
- Richard B. Schwab
- Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center
- Rebecca Shatsky
- Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center
- Steven C. Plaxe
- Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center
- Andrew Sharabi
- Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center
- Edward Stites
- Integrative Biology Laboratory, Salk Institute for Biological Studies
- Jacob J. Adashek
- Department of Internal Medicine, University of South Florida, H. Lee Moffitt Cancer Center & Research Institute
- Ryosuke Okamura
- Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center
- Suzanna Lee
- Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center
- Scott M. Lippman
- Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center
- Jason K. Sicklick
- Center for Personalized Cancer Therapy and Division of Surgical Oncology, Department of Surgery, UC San Diego Moores Cancer Center
- Razelle Kurzrock
- Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center
- DOI
- https://doi.org/10.1038/s41467-020-18613-3
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 9
Abstract
A molecular tumor board (MTB) is often used as a platform that integrates clinical and molecular parameters for clinical decision making. Here, the authors review the outcome of 715 cancer patients presented at their institution’s MTB, and demonstrate that patients who received a MTB-recommended regimen received therapy that was better matched to their alterations and achieved better clinical outcomes.
